PortalPublikationenA novel molecular disease classifier for psoriasis and eczem...

A novel molecular disease classifier for psoriasis and eczema

Standard

A novel molecular disease classifier for psoriasis and eczema. / Garzorz-Stark, Natalie; Krause, Linda; Lauffer, Felix; Atenhan, Anne; Thomas, Jenny; Stark, Sebastian P; Franz, Regina; Weidinger, Stephan; Balato, Anna; Mueller, Nikola S; Theis, Fabian J; Ring, Johannes; Schmidt-Weber, Carsten B; Biedermann, Tilo; Eyerich, Stefanie; Eyerich, Kilian.

in: EXP DERMATOL, Jahrgang 25, Nr. 10, 10.2016, S. 767-774.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Garzorz-Stark, N, Krause, L, Lauffer, F, Atenhan, A, Thomas, J, Stark, SP, Franz, R, Weidinger, S, Balato, A, Mueller, NS, Theis, FJ, Ring, J, Schmidt-Weber, CB, Biedermann, T, Eyerich, S & Eyerich, K 2016, 'A novel molecular disease classifier for psoriasis and eczema', EXP DERMATOL, Jg. 25, Nr. 10, S. 767-774. https://doi.org/10.1111/exd.13077

APA

Garzorz-Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., Franz, R., Weidinger, S., Balato, A., Mueller, N. S., Theis, F. J., Ring, J., Schmidt-Weber, C. B., Biedermann, T., Eyerich, S., & Eyerich, K. (2016). A novel molecular disease classifier for psoriasis and eczema. EXP DERMATOL, 25(10), 767-774. https://doi.org/10.1111/exd.13077

Vancouver

Garzorz-Stark N, Krause L, Lauffer F, Atenhan A, Thomas J, Stark SP et al. A novel molecular disease classifier for psoriasis and eczema. EXP DERMATOL. 2016 Okt;25(10):767-774. https://doi.org/10.1111/exd.13077

Bibtex

@article{9b8373ff2fbd4837881d01011456edc1,
title = "A novel molecular disease classifier for psoriasis and eczema",
abstract = "Novel specific therapies for psoriasis and eczema have been developed, and they mark a new era in the treatment of these complex inflammatory skin diseases. However, within their broad clinical spectrum, psoriasis and eczema phenotypes overlap making an accurate diagnosis impossible in special cases, not to speak about predicting the clinical outcome of an individual patient. Here, we present a novel robust molecular classifier (MC) consisting of NOS2 and CCL27 gene that diagnosed psoriasis and eczema with a sensitivity and specificity of >95% in a cohort of 129 patients suffering from (i) classical forms; (ii) subtypes; and (iii) clinically and histologically indistinct variants of psoriasis and eczema. NOS2 and CCL27 correlated with clinical and histological hallmarks of psoriasis and eczema in a mutually antagonistic way, thus highlighting their biological relevance. In line with this, the MC could be transferred to the level of immunofluorescence stainings for iNOS and CCL27 protein on paraffin-embedded sections, where patients were diagnosed with sensitivity and specificity >88%. Our MC proved superiority over current gold standard methods to distinguish psoriasis and eczema and may therefore build the basis for molecular diagnosis of chronic inflammatory skin diseases required to establish personalized medicine in the field.",
keywords = "Adult, Aged, Chemokine CCL27, Cohort Studies, Eczema, Female, Fluorescent Antibody Technique, Humans, Male, Middle Aged, Nitric Oxide Synthase Type II, Psoriasis, Journal Article, Research Support, Non-U.S. Gov't",
author = "Natalie Garzorz-Stark and Linda Krause and Felix Lauffer and Anne Atenhan and Jenny Thomas and Stark, {Sebastian P} and Regina Franz and Stephan Weidinger and Anna Balato and Mueller, {Nikola S} and Theis, {Fabian J} and Johannes Ring and Schmidt-Weber, {Carsten B} and Tilo Biedermann and Stefanie Eyerich and Kilian Eyerich",
note = "{\textcopyright} 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2016",
month = oct,
doi = "10.1111/exd.13077",
language = "English",
volume = "25",
pages = "767--774",
journal = "EXP DERMATOL",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - A novel molecular disease classifier for psoriasis and eczema

AU - Garzorz-Stark, Natalie

AU - Krause, Linda

AU - Lauffer, Felix

AU - Atenhan, Anne

AU - Thomas, Jenny

AU - Stark, Sebastian P

AU - Franz, Regina

AU - Weidinger, Stephan

AU - Balato, Anna

AU - Mueller, Nikola S

AU - Theis, Fabian J

AU - Ring, Johannes

AU - Schmidt-Weber, Carsten B

AU - Biedermann, Tilo

AU - Eyerich, Stefanie

AU - Eyerich, Kilian

N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2016/10

Y1 - 2016/10

N2 - Novel specific therapies for psoriasis and eczema have been developed, and they mark a new era in the treatment of these complex inflammatory skin diseases. However, within their broad clinical spectrum, psoriasis and eczema phenotypes overlap making an accurate diagnosis impossible in special cases, not to speak about predicting the clinical outcome of an individual patient. Here, we present a novel robust molecular classifier (MC) consisting of NOS2 and CCL27 gene that diagnosed psoriasis and eczema with a sensitivity and specificity of >95% in a cohort of 129 patients suffering from (i) classical forms; (ii) subtypes; and (iii) clinically and histologically indistinct variants of psoriasis and eczema. NOS2 and CCL27 correlated with clinical and histological hallmarks of psoriasis and eczema in a mutually antagonistic way, thus highlighting their biological relevance. In line with this, the MC could be transferred to the level of immunofluorescence stainings for iNOS and CCL27 protein on paraffin-embedded sections, where patients were diagnosed with sensitivity and specificity >88%. Our MC proved superiority over current gold standard methods to distinguish psoriasis and eczema and may therefore build the basis for molecular diagnosis of chronic inflammatory skin diseases required to establish personalized medicine in the field.

AB - Novel specific therapies for psoriasis and eczema have been developed, and they mark a new era in the treatment of these complex inflammatory skin diseases. However, within their broad clinical spectrum, psoriasis and eczema phenotypes overlap making an accurate diagnosis impossible in special cases, not to speak about predicting the clinical outcome of an individual patient. Here, we present a novel robust molecular classifier (MC) consisting of NOS2 and CCL27 gene that diagnosed psoriasis and eczema with a sensitivity and specificity of >95% in a cohort of 129 patients suffering from (i) classical forms; (ii) subtypes; and (iii) clinically and histologically indistinct variants of psoriasis and eczema. NOS2 and CCL27 correlated with clinical and histological hallmarks of psoriasis and eczema in a mutually antagonistic way, thus highlighting their biological relevance. In line with this, the MC could be transferred to the level of immunofluorescence stainings for iNOS and CCL27 protein on paraffin-embedded sections, where patients were diagnosed with sensitivity and specificity >88%. Our MC proved superiority over current gold standard methods to distinguish psoriasis and eczema and may therefore build the basis for molecular diagnosis of chronic inflammatory skin diseases required to establish personalized medicine in the field.

KW - Adult

KW - Aged

KW - Chemokine CCL27

KW - Cohort Studies

KW - Eczema

KW - Female

KW - Fluorescent Antibody Technique

KW - Humans

KW - Male

KW - Middle Aged

KW - Nitric Oxide Synthase Type II

KW - Psoriasis

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/exd.13077

DO - 10.1111/exd.13077

M3 - SCORING: Journal article

C2 - 27193975

VL - 25

SP - 767

EP - 774

JO - EXP DERMATOL

JF - EXP DERMATOL

SN - 0906-6705

IS - 10

ER -